Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.

Vinay Prasad (YouTube/FDA)

More from Cell Therapies

More from R&D